The specialty pharmaceutical market witnesses fierce competition with numerous top notch players; such as such as Amgen, Pfizer, Eli Lilly, Roche, Johnson & Johnson and Novo Nordisk. For more mail me: pr@konceptanalytics.com

1. View Report Details
The US Specialty Pharmaceutical Market
----------------------------------------------------2013

2. View Report Details
Executive Summary
Specialty pharmaceuticals are defined as a new, rapidly growing drugs and biologics that are manufactured as a result of continued
advancements in drug technology and design. These pharmaceuticals are specialized, high cost products which can be difficult to
administer and may require patient monitoring. Specialty pharmaceuticals are utilized as complex therapies for complex chronic
diseases such as cancer, hemophilia, multiple sclerosis, HIV, hepatitis C, apart from others. Some of the specialized drugs that are
used for treating such conditions meet all the three H’s: High Cost, High Complexity and High Touch and they require extensive
education for safe and cost-effective use. The specialty pharmaceuticals are mostly injectable or infused medicines but may also
encompass oral medications.
Specialty pharmacy is a special class of provider that are primarily responsible for distributing and dispensing the pharmaceutical as
specialty pharmaceutical require specialized shipping and temperature-controlled storing and handling. Specialty pharmacy can be
owned by stand-alone companies or large pharmacy chains. However, some drug wholesalers are also capable of shipping the
specialty pharmaceuticals. There exists a substantial incentive for companies to research and develop products that address the
unmet need of the patients as the specialty pharmaceutical market has the ability to sustain the high cost of these products thereby
additionally offering a business perspective for the biopharmaceutical companies.
The key factors driving growth of the US specialty pharmaceutical industry include accelerating US aging population, ameliorating
economic condition, increased life expectancy, and increasing healthcare expenditure. Some of the noteworthy trends and
developments of this industry include rising Medicare enrollment, novel specialty products in pipeline, conversion of patents to generic
drugs, increased spending on specialty drugs and ongoing merger & acquisition activities. However, the growth of the industry is being
hindered by lack of rigorous clinical trials, sluggish pace of innovation and inappropriate use of therapeutic drugs.
The specialty pharmaceutical market witnesses fierce competition with numerous top notch players; such as such as Amgen, Pfizer, Eli
Lilly, Roche, Johnson & Johnson and Novo Nordisk; operating in the market place along with small budding players. The fierce
competition prevailing in the US specialty pharmaceutical industry has been studied on a number of parameters such as competing
drugs, mail pharmacies and distributors. The company profiles of leading aforementioned players in the market are also presented in
the report.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of
the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS
Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several
independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and
tests.

3. Special pharmaceutical category can be classified into one of the following types: Orphan Drugs,
Biotechnology Products, Blood Products and products defined by complex medical condition.
• The global pharmaceutical market has been consistently growing
since almost a decade. Over the past couple of years, a huge
success is being noted in the phase III trials of therapeutic drugs.
Marking an incline of ….%, the global pharmaceutical market
reached US$.… billion at the end of 2012, compared to US$....
billion during the prior year.
US$ Billion
Global Pharmaceutical Market (2003-2013E)
•The pharmaceutical market in the US inclined by ….%, reaching
US$.... billion in 2012, compared to US$.... billion during the
previous year. Furthermore, the growth of the pharmaceutical
industry in the US was noted at a CAGR of …..% during the period
spanning 2008 to 2012.
2013E
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
• North America held a healthy share of ….% of the global
pharmaceutical market at the end of 2012. Europe was the second
largest market with ….% share, followed by combined share of
….% of Asia, Africa, India and Australia.
The US Pharmaceutical Market (2008-2012)
US$ Billion
Regional Percentage Share in Global Pharmaceutical Market (2012)
2008
NA
Europe
As, Af, In, Aus
Japan
Latin America
Others
2009
2010
2011
2012

4. Specialty pharmaceuticals are specialized, high cost products which can be difficult to administer and
may require patient monitoring and are used for treating complex chronic conditions.
The US Traditional Pharmaceutical Market (2008-2012)
• The traditional pharmaceutical sales in the US consistently
increased till 2011. However, the overall sales of the traditional
pharmaceutical were noted at US$..... billion in 2012, down by
….%, compared to US$..... billion in 2011.
US$ Billion
• The sales of the specialty pharmaceuticals increased to US$.....
billion in 2012. This represented a remarkable incline of ….%,
compared to US$.... billion during the prior year. Further, the
growth of the aforementioned segment was recorded at an
impressive CAGR of …..%, during the period spanning 2008 to
2012.
2008
2009
2010
2011
2012
Specialty Market Share by Dispensing Channels (2012)
US$ Billion
The US Specialty Pharmaceutical Market (2008-2012)
• Growth of specialty drug is viewed as one of the major trend of
the industry. In the category of specialty drugs, mail delivery and
retail dispensing channels held an equal share of ….% each during
2012 immediately followed by physician office with ….% share. The
other dispensing channels include outpatients, home health and
inpatient with shares of ….%, …% and ….%, respectively.
Mail Delivery
2008
2009
2010
2011
2012
Retail
Physician Office
Outpatient
Home Health
Inpatient

5. The key factors driving growth of the US specialty pharmaceutical industry include accelerating US aging
population, increased life expectancy, and increasing healthcare expenditure.
Share of Constituents of Specialty Pharmaceutical Market (2012)
• In 2012, oncology represented highest sales of US$.... billion
immediately followed by rheumatoid arthritis with sales equivalent
to US$.... billion. In terms of percentage share, oncology accounted
for a healthy ….% of the total sales in 2012. Rheumatoid arthritis
was the second largest contributor with moderate ….% share
followed by …% share of HIV/AIDS therapeutic area.
• During 2012, AmerisourceBergen commanded a staggering share
of ….% while McKesson accounted for ….% of the same. Metro
Medical and CuraScript held respective shares of ….% and ….%.
Oncology (incl. oral solids)
Rheumatoid arthritis/Crohn's
HIV/AIDS (including oral solids)
Multiple sclerosis
Renal
• The leading two companies; Express Script and CVS Caremark;
accounting for combined share of …..% of the total market in terms
of specialty mail pharmacy market during 2012. Furthermore,
Express Script, CVS Caremark and Walgreen represented shares
of …..%, …..% and ….%, respectively.
IVIG/ Hemophilia
Specialty Distributors Market Share (2012)
Specialty Mail Pharmacy Market Share (2012)
Express Script
Walgreens
ABC
McKesson
Metro Medical
CuraScript
Others
CVS Caremark
Diplomat Specialty Pharmacy
Omnicare
Retail and Other Specialty Pharmacies

6. Specialty pharmacy services are divided sub divided into four types namely; Packaging and Delivery,
Reimbursement, Inbound and Outbound Clinical Support and Compliance and Persistence Program.
Percentage Share of Leading 10 Specialty Drugs in the US
The US Specialty Pharmaceutical Market (2008-2017E)
US$ Billion
by Revenue (2012)
Humira
Lantus
Remicade
Abilify
Enbrel
Rituxan
Seretide/Advair
Cymbalta
Neulasta
2008
2009
2010
2011
2012 2013F 2014F 2015F 2016F 2017F
 Accounting for ….% share, Humira was the leading drug in the US marketplace in 2012, immediately followed by Abilify with ….% share.
Further, Seretide, Lantus and Enbrel accounted for equal share of …..%, each, of the sales of leading 10 drugs. Other drugs which dominated
the marketplace during the cited period include Cymbalta, Remicade, Rituxan, Neulasta and Crestor.
 The US specialty pharmaceutical market is forecasted to increase by …..% to reach US$.... billion by the end of 2013, compared to US$....
billion in the previous year. Further, the market is forecasted to reach US$..... billion by the end of 2017 thus registering growth at a remarkable
CAGR of …..% during the period spanning 2012 to 2017.
 The specialty pharmaceutical market witnesses’ fierce competition with numerous top notch players operating in the marketplace along with
small budding players steeply inclined towards discovering and devising novel therapeutic molecules which address the unmet needs of the
concerned disease area. This represents the evolution of specialty pharmaceutical industry over the past couple of years. Specialty distribution
represents lucrative growth opportunity for the distributors as it is one of the largest and rapidly growing segments. Specialty distribution is a
densely consolidated industry with handful players dominating the marketplace as compared to the traditional drug distribution channels.
Specialty margins tend to be a bit higher as compared to the overall distribution average due to higher margins in the related services.
Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa

7. Table of Contents
1.
Overview
1.1 Specialty Pharmaceuticals Vs Traditional Drugs
1.2 Applications of Specialty Pharmaceuticals
1.3 Specialty Pharmacy Services
1.3.1 Packaging and Delivery Services
1.3.2 Reimbursement Services
1.3.3 Inbound and Outbound Clinical Support
1.3.4 Compliance and Persistence Program
1.4 Specialty Product Distribution
1.4.1 Distribution Services
1.5 Specialty Pharma Manufacturer Services
1.6 Value Proposition of Specialty Pharmacy
2. Market Size
2.1 Pharmaceutical Market
2.1.1 Global Analysis
2.1.2 Regional Analysis
2.2 The US Specialty Pharmaceutical Market
-Market Value
-Traditional Vs Specialty
-Sales by Customers
-Sales by Dispensing Channels
2.2.1 The US Specialty Pharmaceutical Market by
Therapeutic Area
2.2.2 Specialty Pharmacy in the US
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Accelerating US Aging Population
3.1.2 Increasing Life Expectancy Rate in the US
List of Charts & Tables
List of Charts
Flow of Products within the Specialty Pharmacy Channel
SP Benefits Model
Global Pharmaceutical Market (2003-2013E)
Global Pharmaceutical Market – by Region (2012)
Regional Percentage Share in Global Pharmaceutical Market (2012)
The US Pharmaceutical Market (2008-2012)
The US Traditional Pharmaceutical Market (2008-2012)
The US Specialty Pharmaceutical Market (2008-2012)
Percentage Share of Traditional and Specialty Pharmaceutical in the US
(2012)
Distributor Specialty Sales by Customer (2012)
Specialty Market Share by Dispensing Channels (2012)
Share of Constituents of Specialty Pharmaceutical Market (2012)
Share of Therapeutics in Specialty Pharmacy Market (2012)
The US Aging Population (2008-2012)
The US Life Expectancy Rate (2006-2013E)
The US Healthcare Expenditure per Capita (2006-2012E)
GNI of the US (2006-2012)
Medicare Enrollments (2005-2014E)
FDA Approval of New Molecule Entities (2003-2012)
Growth in Specialty Drug v/s Non-Specialty Drug Spend
Specialty Drug Spending Trend (2012 & 2015E)
Specialty Drug Patent to Generic Conversions (2013E-2020E)
Biotechnology Drugs Currently in Development (2012)
Percentage Share of Leading 10 Specialty Drugs in the US – by Revenue
(2012)
Specialty Mail Pharmacy Market Share (2012)
Specialty Distributors Market Share (2012)
Novo Nordisk Revenue Share by Business Segments (2013)
Novo Nordisk Revenue Share by Business Segments (2013)
Novo Nordisk Revenues & Net Income (2009-2013)
Amgen’s Revenue Share by Business segment (2012)
Amgen’s Revenues and Net Income (2008-2012)

8. 3.1.3 Rising Incidences of Complex Chronic Diseases
3.1.4 Rising Pharmaceutical Sales
3.1.5 Healthcare Reforms
3.1.6 Escalating Healthcare Expenditure in the US
3.1.7 Ameliorating Economic Conditions
3.1.8 Patents Expiry of Bio Drugs
3.2 Trends and Developments
3.2.1 Increased Acceptance of Specialty Therapy
3.2.2 Mergers and Acquisitions
3.2.3 Rising Medicare Enrollments
3.2.4 Rising Number of New Molecular Entities
3.2.5 Increased Spending on Specialty Drugs
3.2.6 Shift from Specialty Drug Patents to Generic Conversion
3.2.7 Novel Specialty Product in Pipeline
3.3 Challenges
3.3.1 Lack of Rigorous Clinical Trials
3.3.2 Rising Price Pressure
3.3.3 Inadequate Innovations
3.3.4 Inappropriate Use of Therapeutic Drugs
4. Competitive Landscape
4.1 Competition by Drugs
4.2 Competition by Mail Pharmacy
4.3 Competition by Specialty Distributor
5. Company Profiles
5.1 Novo Nordisk
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
-Focus on Product Innovation
-Establishing Presence in Obesity & Inflammation Treatments
5.2 Amgen Inc.
5.2.1 Business Overview
5.2.2 Financial Overview
Pfizer’s Revenue Share by Business Segments (2013) Pfizer’s Revenues &
Net Income (2009-2013)
Roche’s Revenue by Business Segments (2013)
Roche Holding’s Revenue and Net Income (2009-2013)
Johnson & Johnson’s Revenue Share by Business Segments (2013)
Johnson & Johnson’s Revenues and Net Income (2009-2013)
Eli Lilly’s Revenue and Net Income (2009-2013)
The US Specialty Pharmaceutical Market (2008-2017E)

9. 5.2.3 Business Strategies
-Business Expansion through Acquisitions
-Advancements in Product Pipeline
5.3 Pfizer Inc.
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
-Focus on Novel Product Development
-Growth through Strategic Acquisitions
5.4 Roche Holdings AG
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
-Ceaseless Focus on R&D
-Expansion through Strategic Collaboration
5.5 Johnson & Johnson
5.5.1 Business Overview
5.5.2 Financial Overview
5.5.3 Business Strategies
-Novel Product Launch
-Growth through Acquisitions
5.6 Eli Lilly and Company
5.6.1 Business Overview
5.6.2 Financial Overview
5.6.3 Business Strategies
-Focus on Novel Molecule Development
-Expansion through Strategic Acquisitions
6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis
List of Tables
Specialty Pharmaceuticals - Key Application Areas
Specialty Pharmacy v/s Specialty Distributors
Key Players Providing Manufacturer Services
The US Specialty Pharmaceutical Market Constituents (2012)
Specialty Pharmacy Market – by Value (2011 & 2012)
Expiry of Bio Drugs’ Patents by Company (2013-2019)
Comparison of Traditional Therapy and Specialty Therapy
Specialty Pharmaceutical M&A (2007-2013)
Larger Specialty Distribution Transactions (2005-2012)
Projected Specialty Generic Launches (2013-2015)
Specialty Drugs under Development
Selected Product Launches (2012-2016)
Leading 10 Specialty Drugs in the US (2012)
Dependent & Independent Variables (2008–2012)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Outpu

10. View Report Details
Contact Us:
These are abridged and sanitized sample pages from the comprehensive report on the The US Specialty Pharmaceutical
Market Report . To know more about this report or for any customized research requirement, please contact the following:
Koncept Analytics
Vikas Gupta
BD Manager
CS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T. +91-120-4130959
C: +91-9811715635
vikas@konceptanalytics.com
www.konceptanalytics.com